Specifically, Ixchiq will be tested in children aged one to 11 and pregnant women in countries that may be affected by a chikungunya outbreak ... review in the country, with a decision due ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...

The virus has now been identified in over 110 countries in Europe, Asia, Africa and the Americas, and the number of cases in India is rapidly increasing due to the current outbreak in the Indian ...

The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data ... which would represent the first approval in an endemic country. Valneva submitted label extension applications to the ...

Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ, in 304 children.

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data ... which would represent the first approval in an endemic country. Valneva submitted label extension applications to the U.S. Food and ...